NEW YORK (GenomeWeb News) – Two new Nature Genetics studies suggest that mutations affecting a gene called SMIM1 are behind the rare "Vel" blood group — named for the lack of Vel antigen expression on red blood cells of those affected.
Registering provides access to this and other free content.
Already have an account?Login Now.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.
Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.
In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.
This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.